Abstract
Technological advances in the ability to analyze patterns of gene expression and signal transduction pathway activation are improving our understanding of cancer. Previously unrecognized molecular subsets and pathway profiles that convey predictive and prognostic information about individual cancer patients are being identified. Patients with glioblastoma, the most common malignant primary brain tumor of adults, stand to benefit considerably from these advances. Recent data suggest that morphologically indistinguishable glioblastomas have distinct classes of causal oncogene activation, and that these subclasses may be targetable by oncogene/signaling pathway specific therapies. Oncogene/signaling pathway inhibitors show great promise for the treatment of patients with some types of cancer, but their clinical application for glioblastoma has been severely limited by an inability to determine which inhibitor is most likely to benefit a specific patient. Identifying biologically relevant molecular subsets of glioblastoma and detecting pathway profiles that can be used to guide patient therapy are likely to result in significant improvement in the survival of glioblastoma patients.
Keywords
Affiliated Institutions
Related Publications
Diagnosis and Treatment of Metastatic Colorectal Cancer
Advances in molecular profiling of metastatic CRC facilitate the ability to direct treatments to the biologic features of the tumor for specific patient subsets. Although cures ...
Loss of the Mismatch Repair Protein MSH6 in Human Glioblastomas Is Associated with Tumor Progression during Temozolomide Treatment
Abstract Purpose: Glioblastomas are treated by surgical resection followed by radiotherapy [X-ray therapy (XRT)] and the alkylating chemotherapeutic agent temozolomide. Recently...
Stem Cell–Related “Self-Renewal” Signature and High Epidermal Growth Factor Receptor Expression Associated With Resistance to Concomitant Chemoradiotherapy in Glioblastoma
Purpose Glioblastomas are notorious for resistance to therapy, which has been attributed to DNA-repair proficiency, a multitude of deregulated molecular pathways, and, more rece...
Primary and secondary glioblastomas: From concept to clinicaldiagnosis
Glioblastomas may develop de novo (primary glioblastomas) or through progression from low-grade or anaplastic astrocytomas, (secondary glioblastomas). These subtypes of glioblas...
Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Abstract Selumetinib (AZD6244, ARRY-142886) is a selective, non–ATP-competitive inhibitor of mitogen-activated protein/extracellular signal–regulated kinase kinase (MEK)-1/2. Th...
Publication Info
- Year
- 2003
- Type
- review
- Volume
- 2
- Issue
- 3
- Pages
- 242-247
- Citations
- 71
- Access
- Closed
External Links
Social Impact
Social media, news, blog, policy document mentions
Citation Metrics
Cite This
Identifiers
- DOI
- 10.4161/cbt.2.3.369